Invivyd announces Phase 1/2 data for VYD2311

Invivyd (IVVD) announced positive data from its ongoing Phase 1/2 clinical trial of VYD2311, Invivyd’s novel monoclonal antibody candidate designed to be a superior alternative to COVID-19 vaccination for the broad population as frontline protection in a convenient form, as well as to provide a novel, potent, long-acting option for the treatment of COVID-19. Recruitment completed and all doses administered for VYD2311 ongoing Phase 1/2 clinical trial evaluating 3 routes of administration. Phase 1/2 clinical data for VYD2311 to date are positive for both safety and pharmacokinetics, and are supported by antiviral activity data from Invivyd’s standard virologic assessments. Phase 1/2 clinical data, combined with antiviral assessment and COVID-19 antiviral correlate of protection data, including Invivyd’s Phase 3 CANOPY clinical trial data for pemivibart, support a potential clinical profile for VYD2311 with superior efficacy, safety, and durability to COVID-19 vaccines.